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doi:10.1016/j.ejvs.2009.12.020Abstract For the treatment of congenital vascular malformation (CVM), conservative,
endovascular and/or surgical treatment have been sporadically attempted according to the
type, location and clinical manifestations of the vascular lesions. At current practice, with
no established treatment guidelines for CVM patients, there is much room for ineffective inter-
ventions and occurrence of complications related with the treatment.
Therefore, it is important to select proper candidates for the endovascular or surgical treat-
ment in CVM patients to avoid ineffective treatment and its complications and to obtain better
treatment results.
We describe the basic considerations before the selection of candidates for percutaneous
embolo-sclerotherapy in patients with CVM based on our own experiences at a specialised
CVM clinic.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Congenital vascular malformation (CVM) is a congenital
anomaly that is believed to occur as a result of an error in
the development of vascular system during the foetal life.1
It varies in the component of vascular structures, site of
involvement and clinical presentations according to theeting 3e6 September, 2009,
, Oslo, Norway.
3410 0040.
ty for Vascular Surgery. Publishetiming of the occurrence of the developmental error during
embryogenesis.
The clinical manifestations vary from a small skin marker
(capillary malformation of the skin) or an asymptomatic
vascular mass to a serious anomaly with disfigurement,
symptoms (pain, bleeding, etc.), or malfunction of the
limb. A deep-seated vascular malformation may be
subclinical until a provoking event stimulates the lesion.
CVMs involving the head or neck are more likely to cause
cosmetic defects, mucosal bleeding and speech disorder
due to tongue involvement or malposed dentition. These
may even lead to blindness.d by Elsevier Ltd. All rights reserved.
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pain, discomfort, asymmetry or functional impairment. In
patients with a mixed form of vascular malformation, the
so-called KlippeleTrenaunay syndrome, there are several
mechanisms that are proposed as causes of pain, which
include chronic venous insufficiency, cellulitis, superficial
or deep venous thrombosis, calcification of vascular
malformation, pain with enlargement of the lesion, intra-
osseous vascular lesion, arthritis or neuropathic pain.2
Sometimes vascular malformations cause limb length
discrepancy due to bone overgrowth or undergrowth.3
Arterio-venous malformation (AVM) involving bone can
cause anomalous bone growth or pathologic fracture
(Fig. 1). Furthermore, chronic and high-flow arterio-venous
shunts may cause high-output cardiac failure and
cardiomegaly.
Surgical treatment of CVM
Surgical removal of vascular malformations has been
recommended only for select patients due to the risk of
massive haemorrhage during the operation, unavailability
to remove all vascular malformation lesions and high
recurrence and complication rates.4,5 Furthermore, it is
reported that certain CVM lesions can be aggravated by
incomplete surgical excision or feeding artery ligation due
to rapid collateralisation from adjacent arteries and further
limit access to the nidus for future treatment.6 Malan and
Puglionisi7 proposed that pressure or flow changes in the
vascular malformation lesion can reactivate dormant
angiopoietic cells and stimulate endothelial cell growth.
Growth factors, such as vascular endothelial growth factor
(VEGF), angiopoietin-1 (Ang-1) and angiopoietin 2 (Ang-2),
have been reported as the most potent regulators for
neo-vascularisation.8 Recently, some authors reported
increases in serum levels of Ang-2- and Tie-2-soluble
receptor in patients with extensive AVM.9
Accordingly, current trends in the treatment of CVMs
largely depend on endovascular treatment. Fig. 2 demon-
strates the treatment of patients with vascular malforma-
tions in Samsung Medical Center in Seoul, Korea.
Loose10 has established that the surgical treatment of
venous malformations (VMs) has different purposes basedFigure 1 Anomalous bone growth and pathologic fracture in a pat
hand showing skin mark and deformity, B) bone X-ray shows multi
tures, which are concurrent with arteriovenous malformation lesioon the pathological form and the type of malformation: to
improve haemodynamic abnormality (such as in patients
with venous hypertension), eliminate a confined (limit-
ed)VM, or to reconstruct central or visceral vein defects.
Before surgical treatment of vascular malformations,
preoperative embolo-sclerotherapy is a helpful adjunct to
reduce intra-operative haemorrhage. There are other roles
of surgical treatment for patients with vascular malfor-
mations, such as plastic surgery for cosmetic purposes
after endovascular treatment of vascular malformations
(Fig. 3) and limb amputation for patients with severe
uncorrectable joint contracture or limb-length
discrepancy.
Endovascular treatment of CVMs
As described above, endovascular treatment is the main
treatment modality for patients with CVM. Endovascular
treatment includes sclerotherapy, embolisation or endo-
vascular thermal ablation.
For sclerotherapy of vascular malformation, high-
concentration ethanol is most commonly used sclerosant,
whereas ethanolamine oleate, bleomycin, N-butyl cyano-
acrylate (NCBA), polidocanol or sodium tetradecyl sulphate
(STS) are used for select patients.
The access route to the target vascular lesion is direct
percutaneous, transvenous or trans-arterial according to
the location of the vascular lesion and accessibility to the
target lesion. For an efficient sclerotherapy, the following
factors are required: (1) available access route to the
target lesion, (2) a sclerosing agent that can cause damage
of the target vascular tissue, (3) ample contact time
between sclerosing agent and target vascular tissue and (4)
low risk of local or systemic side effects of the sclerosing
agent.
Among several agents used for sclerosing or embolic
purposes, ethanol is the most powerful agent and, there-
fore, carries a higher risk of local and systemic side effects.
Other agents, such as ethanolamine oleate, polidocanol or
STS, have less powerful sclerosing effects but are followed
by relatively lower complication rates.
Contact (or residing) time of infused sclerosing agent in
the target vascular lesion varies according to the type ofient with arterio-venous malformation (AVM): A) photograph of
ple osteolytic lesions in metacarpal bone and pathologic frac-
n on an angiogram (C).
Figure 2 Treatment of patients (NZ 1459) with congenital vascular malformations (CVMs) at CVM Clinic, Samsung Medical
Center, Seoul, Korea (1994e2009).
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drainage vein (not visible, delayed or early appearance on
a venogram) and the amount of the infused sclerosant.
To prolong the contact time of sclerosant in target vascular
lesions, adjuvant manoeuvres are attempted during
sclerotherapy. For this purpose, transvenous placement of
an occluding balloon catheter in the drainage veins, coil
embolisation of the AVM nidus, manual compression of
drainage vein under the fluoroscopy, infusion of vasospastic
agent into the drainage veins before injection of scle-
rosant11 or occlusion of proximal feeding artery with
pneumatic cuff can be used during the sclerotherapy.
An important factor to keep in mind during these
manoeuvres is a potential risk of haemodynamic decom-
pensation with the release of compression due to a sudden
shift of sclerosant into the systemic and pulmonary
circulation.
Complications of ethanol sclerotherapy can be cat-
egorised into local and systemic. Local complications
include surrounding soft tissue injuries, including skin and
nerve damage. In our institution, we have experienced
local soft tissue injuries (11.9%) and nerve damage (8.6%)
after ethanol sclerotherapy. Sixty percent of soft tissue
damage and 85% of nerve impairment were spontaneously
resolved.12 Other rare local complications that have been
reported include gait instability due to calf muscle fibrosis
or ankle contraction, and deep vein thrombosis.13 SystemicFigure 3 Multidisciplinary approach for a patient with facial arter
C, embolo-sclerotherapy with coil and 100% ethanol; and D, Aftercomplications of ethanol sclerotherapy included central
nervous system depression, hypoglycaemia, haemolysis,
hypertension, pulmonary vasospasm and pulmonary hypo-
tension.14,15 Cardiopulmonary collapse secondary to the
pulmonary vasoconstriction is the most serious complica-
tion after ethanol sclerotherapy. To prevent this disaster,
we recommend an infusion dose of ethanol below 1 ml kg1
of body weight with monitoring of pulmonary artery pres-
sure during and after ethanol sclerotherapy. In the case of
pulmonary hypertension, we use intravenous nitroglycerin.
Endovenous laser and radiofrequency ablation thera-
pies, which have been used for the treatment of leg
varicosities, have recently been attempted in patients with
VMs of the lower extremities.16,17 This type of endovascular
treatment can be attempted for patients with symptomatic
venous insufficiency of the lower extremity due to trun-
cular type VM (e.g., marginal vein or varicosities) to relieve
symptom of venous insufficiency by ablating incompetent
venous reflux channels.Proper selection of patients for endovascular
treatment of CVMs
The requirements for successful treatment of CVMs are
functionally and cosmetically satisfactory results, no
recurrence and no serious complication related to theiovenous malformation (AVM): A, Before treatment; B, CT scan;
surgical removal and skin graft.
Figure 4 Venograms showing venous malformation (VM) lesion with drainage vein (arrow, left) and no visible drainage vein (right).
S52 Y.-W. Kimtreatment. However, this is difficult to achieve in all
patients. Before the treatment of vascular malformations,
proper selection of patients is crucial to avoid unnecessary
interventions and their complications. It is important to
consider the expected clinical course of the lesion, age of
patient, location of the vascular lesion, chief complaint and
expected complications related with the treatment.
In practice, it is difficult to predict the natural course
of vascular malformations. Vascular malformations usually
grow with the body mass. Therefore, younger patients
have a greater potential of the lesion growth than adult
patients.
The type and location of CVMs result in different
prognosis and clinical significance. Certain types of vascular
malformations (e.g., AVM or infiltrative, extratruncular
type of vascular malformation) have greater potential to
proliferate than other types. It is usually believed that
vascular malformation caused by earlier developmental
arrest during foetal life has a greater potential of prolif-
eration by provoking stimulus due to its undifferentiated
nature of the component vascular tissue.
CVMs at certain anatomic locations have more serious
clinical significance with regard to cosmesis (e.g., head and
neck), functionality (e.g., limb) or even mortality (e.g.,
close to airway, brain). If unavailable to extirpate all
lesions of vascular malformation, the focus should be on
the chief complaint of the patient. For example, when we
encounter a patient with occasionally detected subcuta-
neous vascular malformations at the head and neck region,
which are cosmetically acceptable and asymptomatic, we
do not recommend intervention.
Ethanol sclerotherapy of vascular malformations close to
the skin has a higher risk of skin damage than in the deep-
seated lesions. For these patients, another sclerosing agent
can be used to avoid chemical burn by ethanol injection.
VMs are known to have a relatively benign clinical course,
except intermittent episodes of thrombophlebitis in theanomalous venous tissue. When VMs are located at the
antecubital fossa close to nerves in the hand and fingers,
sclerotherapy may cause adjacent nerve damage, resulting
in motor or sensory impairment of the hand or fingers,
although most of the nerve complications are transient. We
observed that nerve damage developed more often in
upper extremities than in lower extremities after treat-
ment of CVMs.
Proper selection of patients with VM
VMs are low-flow vascular malformations with relatively
benign natural course. Truncular type of VMs occurs as
ectasia, aplasia or hypoplasia of the deep or superficial
venous system (marginal vein or varicosity), while extra-
truncular type is more common and composed of non-
proliferating ectatic small venous channels infiltrating into
the surrounding tissue.
To determine factors predicting good response to the
sclerotherapy in patients with VMs, we retrospectively
analysed demographics (age and gender), clinical features
(location, size, depth of involved tissue, presence of asso-
ciated lymphatic malformation, magnetic resonance
imaging (MRI) findings and characteristics of drainage vein
on venogram (Fig. 4)) and treatment variables (number of
sclerotherapy sessions, maximal concentration and dosage
of ethanol and adjuvant therapy) to determine predictors
of good response to ethanol sclerotherapy.18
We defined ‘good response’ to sclerotherapy as marked
improvement in a questionnaire survey with regard to
clinical symptoms, function and cosmetic satisfaction in
conjunction with a remarkable size reduction of CVM
lesions on MRI or on radionuclide whole-body blood pool
scintiscan using Tc-99m. Composite outcomes combining
questionnaire results and improvement on imaging study
showed that only 16% of patients had a ‘good response’
after percutaneous ethanol sclerotherapy.
Figure 5 Angiographic types and recommended treatment of arteriovenous malformation (AVM), TA, transarterial access; DP,
direct puncture. (Adapted from Cho et al., 200621).
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model), female gender (odds ratio (OR): 4.49, 95% confi-
dence interval (CI): 1.24e16.28), no or delayed visual-
isation of drainage vein (OR: 9.22, 95% CI: 1.79e47.51) and
a well-defined margin on MRI (OR: 13.38, 95% CI: 2.84e
63.12) were independent predictors of ‘good response’ to
ethanol sclerotherapy.
Proper selection of patients with AVM
AVMs are high-flow vascular malformations composed of
dysmorphic arterial and venous vessels connected directly
to one another without an intervening capillary bed.
Angiographic features of AVMs are characterised as
composition of feeding arteries, the complex mixture of
arterio-venous fistulae, the so-called nidus of AVM and
draining veins.19
In 1993, Houdart et al.20 proposed angiographic classi-
fication of brain AVMs into three types: type I, arteryevein
fistula with <3 feeders and a single draining vein; type II,
arterioleevein fistula with multiple feeders and a single
dominant outflow vein; and type III, arterioleevenule
fistula with multiple arteriole feeders and multiple draining
venules. In our institution, we modified this angiographic
classification and applied it to extracranial AVMs (Fig. 5).21
According to them, type II lesion showed better
outcomes after embolo-sclerotherapy compared to other
types of AVM.
Conclusions
CVM has the potential to change morphology and biology.
Endovascular treatment, including embolo-sclerotherapy,
has become the main treatment modality for patients withvascular malformation. Before the treatment of vascular
malformation, proper selection of patients is crucial to
achieve better treatment results and to avoid unnecessary
complications related with interventions. It is recom-
mended considering an expected clinical course of the
lesion by its type and location of the CVM, age of patient,
chief complaint and expected complications related with
the treatment.
On a diagnostic imaging study, findings predictive of
good response to the endovascular treatment and available
access route to the target CVM lesion can be the other
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